A Multicenter, Open-label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005%, in Pediatric Subjects (Ages 2 to 11 Years) With Plaque Psoriasis
Phase of Trial: Phase I
Latest Information Update: 25 May 2017
At a glance
- Drugs Calcipotriol (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; Mayne Pharma
- 25 May 2017 Phase has changed from 3 to 1 and patient number has also changed fron180 to 75.
- 18 May 2017 Planned number of patients changed from 180 to 75.
- 23 Oct 2013 New source identified and integrated (Oregon Health and Science University Institutional Review Board, IRB00009517).